Sentien Biotechnologies Appoints Dr. Pedro Huertas as Chief Medical Officer
Sentien Biotechnologies, Inc., a clinical-stage biotechnology company developing novel cell therapies to restore balance to the immune system, today announced the appointment of Pedro Huertas, M.D. Ph.D., as its Chief Medical Officer. Dr. Huertas will join Sentien’s executive team and oversee the clinical development of Sentien’s lead product, SBI-101.
Dr. Huertas brings nearly 30 years of pharmaceutical industry experience in research and development, medical affairs, and regulatory affairs in therapeutics for human genetic and metabolic diseases. Prior to joining Sentien, Dr. Huertas was Chief Medical Officer for Eloxx Pharmaceuticals, a company focused on rare and ultra-rare genetic diseases. His prior experience includes clinically-focused positions with big pharmaceutical (Pfizer, Genzyme), small biotechnology (ExSAR Corporation, Amicus Therapeutics, Novazyme), and cell therapy companies (Ocata, StemCells, Inc.). Dr. Huertas is a graduate of Stanford University (M.S., Biochemistry), Harvard University (Ph.D., Cell and Developmental Biology), Harvard Medical School (M.D.), and MIT Sloan School of Management (M.S., Management). He also trained in Internal Medicine, Rheumatology, and Palliative Care at Massachusetts General Hospital.
Read more here.